According to Roche's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.71442. At the end of 2023 the company had a P/S ratio of 3.26.
Year | P/S ratio | Change |
---|---|---|
2023 | 3.26 | -10.64% |
2022 | 3.64 | -30.37% |
2021 | 5.23 | 15.69% |
2020 | 4.52 | 3.85% |
2019 | 4.35 | 19.49% |
2018 | 3.64 | -7.15% |
2017 | 3.93 | -0.43% |
2016 | 3.94 | -19.42% |
2015 | 4.89 | 1.4% |
2014 | 4.82 | 6.83% |
2013 | 4.52 | -28.62% |
2012 | 6.33 | 94.73% |
2011 | 3.25 | 29.52% |
2010 | 2.51 | -20.06% |
2009 | 3.14 | 1.44% |
2008 | 3.09 | -16.77% |
2007 | 3.72 | -16.87% |
2006 | 4.47 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 3.79 | 39.47% | ๐บ๐ธ USA |
Novartis NVS | 4.01 | 47.66% | ๐จ๐ญ Switzerland |
Pfizer PFE | 2.46 | -9.42% | ๐บ๐ธ USA |
Abbott Laboratories ABT | 4.65 | 71.38% | ๐บ๐ธ USA |
Amgen AMGN | 5.14 | 89.25% | ๐บ๐ธ USA |
Sanofi SNY | 2.44 | -10.28% | ๐ซ๐ท France |
Becton Dickinson BDX | 3.43 | 26.43% | ๐บ๐ธ USA |
Merck MRK | 5.53 | 103.67% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | 2.22 | -18.25% | ๐ฌ๐ง UK |